# Zenbexus (iberdomide hydrochloride) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/iberdomide

> The FDA approved Zenbexus (iberdomide hydrochloride), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on August 13, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Zenbexus (iberdomide hydrochloride) FDA approved?

Yes. The FDA approved Zenbexus (iberdomide hydrochloride), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on August 13, 2026. FDA novel drug approvals: "Zenbexus | iberdomide | 8/13/2026 | To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent" [Calendar and source filings](https://sec-api.dev/pdufa/iberdomide)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/iberdomide#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Zenbexus (iberdomide hydrochloride) |
| Codes | CC-220, BMS-986382 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Multiple Myeloma](https://sec-api.dev/indications/multiple-myeloma) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### August 13, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Zenbexus | iberdomide | 8/13/2026 | To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA221075 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260813, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product ZENBEXUS (IBERDOMIDE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA221075%22

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04975997 (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT04975997

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04975997 (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT04975997

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05827016 (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05827016

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05827016 (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05827016

## Same indication

- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)
- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) (BMY)
- [BB2121](https://sec-api.dev/pdufa/bb2121) (BMY)
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin) (GSK)
- [Cemsidomide](https://sec-api.dev/pdufa/cemsidomide) (CCCC)
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel) (JNJ)
- [DARZALEX (daratumumab)](https://sec-api.dev/pdufa/daratumumab) (JNJ)
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab) (BMY)
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab) (PFE)
- [Etentamig](https://sec-api.dev/pdufa/etentamig) (ABBV)
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel) (BMY)
- [Igi, 10%](https://sec-api.dev/pdufa/igi-10) (TAK)
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322) (JNJ)
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide) (JNJ)
- [PHE885](https://sec-api.dev/pdufa/phe885) (NVS)
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide) (BMY)
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig) (JNJ)
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab) (JNJ)
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)

Calendar months: [November 2027](https://sec-api.dev/fda-calendar/2027-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/iberdomide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zenbexus (iberdomide hydrochloride) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/iberdomide

```bibtex
@misc{secapidev_pdufa_iberdomide_20261116,
  title        = {Zenbexus (iberdomide hydrochloride) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/iberdomide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_iberdomide_20261116","title":"Zenbexus (iberdomide hydrochloride) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/iberdomide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
